Abstract
Introduction
Despite recent advances, tuberculosis (TB) remains a major global health problem with 9 million new cases and 1.4 million deaths in 2013.
[1] Critically, the global incidence is decreasing by less than 2% per year, far from the 20% decline required to reach the World Health Organization (WHO) stated goal of eliminating TB by 2050. [2, 3] Patients with pulmonary TB represent~75% of the global disease burden and contribute exclusively to transmission. Rapid, accurate and early detection of Mycobacterium tuberculosis (MTB) in the sputum of TB suspects, and active case finding are key components of the WHO strategy. [4, 5] For decades, the rapid diagnosis of pulmonary TB has relied on sputum acid-fast bacilli (AFB) smear microscopy but its yield is low when compared to mycobacterial culture, which is considered the most sensitive method for diagnosis. [6] Recently developed molecular tests such as Xpert 1 MTB/RIF and GenoType 1 MTBDRplus provide a rapid alternative to culture in patients with high bacterial loads (i.e. sputum AFB smear-positive). However, their overall sensitivity (~90% against culture) in programmatic conditions has been lower than initially anticipated, [7] and particularly poor (~50%) in smear-negative/culture-positive individuals. [8] [9] [10] Other TB diagnostics under development suffer the common limitation of being less sensitive than cultures. [5, 11, 12] For definitive diagnosis, reliance on cultures as the reference method is problematic because the process of decontaminating samples prior to culture is inherently detrimental to mycobacterial viability. As a result, the overall sensitivity of cultures is only 80-85% compared to a composite reference standard, [6] but significantly lower in clinical conditions where the bacterial load in sputum is low (i.e. paucibacillary TB disease) such as certain patients with HIV-infection, [13] children, [14] and extra-pulmonary TB. [15] Other individuals with active disease harboring non-culturable organisms in sputum include subjects with unstable latent TB infection and early sub-clinical disease that have "percolating" organisms, [16] and those with old untreated TB. [17, 18] In addition, "persistent" organisms after antituberculous therapy may represent the paucibacillary TB pool for poor treatment outcomes. [17] Without culture confirmation, paucibacillary TB is rarely identified leading to empirical treatment, over-or underdiagnosis, and increased morbidity and mortality. [19] We have developed the "Totally Optimized PCR (TOP) TB assay", a new nucleic acid amplification test (NAAT) that utilizes a combination of efficient sample processing, novel gene target selection, modern primer design techniques, and an extended PCR for selective target isolation and amplification. The assay is highly specific for Mycobacteria in the MTB complex and therefore is not affected by background genomic noise, which enables detection with heightened sensitivity. We report here results of in silico and in vitro data. To compare accuracy of the TOP TB assay with culture and the leading molecular test (e.g. Xpert MTB/ RIF), we then performed a cross-sectional evaluation using specimens from HIV-infected subjects enrolled into an existing prospective diagnostic study in Uganda.
Materials and Methods
Ethical approvals: The studies were approved by the Institutional Review Boards at Boston University Medical Center, Mbarara University of Science and Technology, and the Uganda National Council for Science and Technology. Samples were shipped to Boston under a Material Transfer Agreement for DNA sequencing.
TOP TB assay
The assay targets a gene (ponA1) involved in the assembly of peptidoglycans in the MTB bacterial wall. [20] The assay's diagnostic primer set (3-ponA-F/R) targets sequences unique to all species in the MTB complex (Section IA, Fig A and Table A in S1 File). Amplicons generated by 3-ponA were detected using a capture-probe colorimetric assay, and the resultant Optical Densities (OD) provided a semi-quantitative measurement of MTB bacillary load. [21] A more detailed description of the TOP TB assay and its associated laboratory methods, including sample processing and DNA extraction, PCR amplification and amplicon detection are provided in S1 File (Sections IA and IB).
PCR genotyping
To establish the presence of MTB DNA, we tested all specimens with primer set 2-ponA-F/Ra (used for genotyping), which targets a section of ponA1 that is sufficiently distant (~1,100 bp) from the 3-ponA target (used for diagnosis) to remain unaffected by amplicons generated with primer 3-ponA (Section IC, Fig A and Table A in S1 File). 2-ponA PCR products were sequenced to distinguish among five possible genetic variants of MTB (genotypes 0 T , 1 T , 2, 3 and 4) (Section IC in S1 File). The sequencing nomenclature (Fig B in S1 File) and the genetic correspondence of 2-ponA genotypes to other familiar MTB whole genome genotyping methods are shown in the Appendix (Fig C and Table B in S1 File).
Clinical study
After completing pre-clinical studies, we tested a convenience sample of discarded sputum specimens obtained from participants enrolled into a cross-sectional TB diagnostic study in Uganda. Table C in S1 File summarizes: the study design, a description of the subjects, and methodology (including reference methods).
Setting. The study was conducted at the Epicentre/ Médecins sans Frontières Laboratory located at Mbarara University of Science and Technology in Mbarara, Uganda. With an estimated TB incidence of 166 cases per 100,000 inhabitants, Uganda is on the WHO list of high burden TB countries; the prevalence of HIV infection among TB patients is 48%.
[1] Mbarara District is situated in the South Western (SW) zone of the Uganda National Tuberculosis and Leprosy Programme (NTLP). According to NTLP laboratory activity reports, 8,423 TB patients were registered in the SW zone (incidence rate 290 per 100,000). Of the 3701 TB suspects from Mbarara District, 668 (18%) were AFB smear-positive, and 68% were HIV infected. [22] Study population. Participants for this study were enrolled into a prospective crosssectional study designed to independently evaluate the diagnostic accuracy of a new AFB smear microscopy method [23] [25] willing to follow the study protocol. Patients were excluded if they had received antituberculous drugs within three days, were too ill to consent, or presented with disseminated or extra-pulmonary TB without cough. Study design and measurements. Participants had a standardized TB evaluation, HIV testing and provided three spontaneously expectorated (!2 mL) sputum samples that included one early morning and two spot samples in a 24-hr period. One of the spot samples (selected by randomization) [24] was tested for direct AFB smear, Xpert MTB/RIF and culture.
Sample handling prior to TOP processing and testing. Specimens from the last 261 HIV-infected participants enrolled into the parent study were available for this study. TOP testing was done on the discarded portion of a pellet processed for Xpert MTB/RIF. A~1mL aliquot was frozen at -80°C for two to six months prior to TOP testing; after thawing, the pellet was washed to remove N-acetyl-L-cysteine / sodium hydroxide solution, [26] processed for TOP and tested in a single batch at the Epicentre laboratory in Mbarara. Study personnel were blind to routine TB results; coded results were later linked via a study identification number.
Standard Laboratory Methods. The Epicentre/ Médecins sans Frontières Laboratory has quality assurance (QA) and quality control (QC) protocols, and well-trained personnel with extensive experience in laboratory based TB research. The appearance of sputa specimens was classified as purulent, mucopurulent, mucosalivary or, salivary by the microbiology technicians according to international laboratory guidelines. [27] We used the light-emitting diode-auramine fluorescence technique (FluorescenS 1 LED system, Bergman Labora, Danderyd, Sweden) for direct AFB microscopy on each specimen and reported the results according to the WHO grading scale. [28] The specimen was then decontaminated using the N-acetyl-L-cysteine (0.5%) / sodium hydroxide (1.5%) method. [26] For the reference culture method, we inoculated 500 μl into one manual-testing MGIT 960 (Becton, Dickinson, Franklin Lakes, NJ). We reported a negative culture result after 56 days of incubation at 37°C. Contamination in MGIT media was ruled out using Ziehl-Neelsen (ZN) microscopy and culture on blood agar. For all positive MGIT cultures, we differentiated between M. tuberculosis and non-tuberculous mycobacteria (NTM) using the SD TB Ag MPT64 Rapid system (SD Bioline, Kyongi-do, South Korea), following the manufacturer's instructions. The GenoType Mycobacterium CM/AS identification kit (Hain Lifescience, Nehren, Germany) was used for identification of NTM. The Xpert 1 MTB/RIF assay (Cepheid, Sunnyvale, CA, U.S.A.) was performed according to the manufacturer's instructions.
Analytical strategy
We report the results according to the Standards for Reporting of Diagnostic Accuracy (STARD) guidelines. [29, 30] We calculated the diagnostic cut-off for TOP OD using a cut-off value of three standard deviations above the mean of the OD values of negative controls (e.g. laboratory cut-off). [31] As a sensitivity analysis, we used receiver operating curve (ROC) tools to determine the cut-off that simultaneously maximized sensitivity and specificity (e.g. ROC cut-off). We estimated per-patient sensitivity and specificity using culture as the reference standard, using all available results to adjudicate TB status. We also estimated per-patient sensitivity and specificity using a Composite Reference Standard (CRS) that included culture, MTB sequencing (e.g. 2-ponA genotyping), a NAAT other than TOP (e.g. Xpert MTB/RIF) and AFB smear, as described. [15, [32] [33] [34] We analyzed patient characteristics according to TOP and culture results using Kruskal-Wallis (for continuous data) and Fisher's exact test (for categorical data), and compared groups using Wilcoxon and Fisher's exact tests. Variables with p< 0.1 and those considered to be clinically significant were included in multivariate logistic and ordinal logistic regression models. In the former we consider correlates with culture+/TOP+ compared to culture-/TOP+ individuals. In the latter, we compare all three outcomes ordinally. For these models we group X-ray results into two categories: Normal/Minimal versus Moderate/ Far Advanced. The models controlled for age, sex, previous TB treatment, sputum appearance, sputum volume (only for first model), and X-ray (2 category).
Results

Preclinical studies
In the preclinical phase, TOP TB's primer set 3-ponA (used for diagnosis) demonstrated: i) excellent analytical sensitivity when clinical sputum samples were "spiked" with Mycobacterium bovis Bacille Calmette-Guérin (Fig D, top in S1 File); ii) semi-quantitative detection capability over a range of MTB loads (Fig D, bottom in S1 File); iii) high analytical specificity, testing negative against a panel of 18 common respiratory bacteria and other microorganisms (Fig E in S1 File), and; iv) high specificity against non-tuberculous mycobacteria (Fig F in S1 File). The 2-ponA primer set (used for sequencing) demonstrated a~8-10% lower analytical sensitivity but similar analytical specificity in the preclinical phase of testing (data not shown).
Clinical study
We then evaluated the TOP TB assay in 261 HIV-infected pulmonary TB suspects enrolled into the parent study between October 2, 2013 and April 11, 2014 (Fig 1) . Table 1 shows characteristics of the study cohort according to culture and TOP TB assay results. As shown in Fig 2, 48/261 (18%) patients were culture-positive, all of which were also TOPpositive. Seventy-four (28%) were culture-negative (N = 64) or contaminated (N = 10) and were TOP-negative; 139 (53%) were culture-negative (N = 137) or contaminated (N = 2) but TOP-positive (Fig 2a) . The distribution of TOP ODs by culture and AFB smear are shown in Fig 2b and 2c , respectively. Of the 139 culture-negative/ TOP-positive samples, 2-ponA sequencing confirmed the presence of MTB DNA in 128 (92%). The sensitivity and specificity of TOP and Xpert MTB/RIF compared to culture or a CRS are shown in Table 2 ; the breakdown of results included in the CRS is shown in Table D in S1 File. We were unable to sequence MTB from 11/139 (8%) culture-negative/ TOP-positive specimens with low TOP OD values (median 0.13, IQR 0.11-0.34).
In univariate analyses that compared culture-positive/TOP-positive vs. culture-negative/ TOP-positive patients (Table 1) , the latter were more likely to be older (P<0Á001); women (P<0Á001); have a salivary sputum (P = 0Á05); have a previous history of TB disease (P = 0Á05), and have early TB disease as measured by sputum AFB smear grade (P<0Á001) and chest radiograph (P = 0Á05). In a multivariate analysis comparing culture+/TOP+ to culture-/TOP+ patients, age (p = 0.003) and gender (p = 0.002) remained statistically significant. In a comparison of all three TOP/culture categories from Table 1 , multivariate results revealed that age (p = 0.02) and gender (p<0.001) were statistically significant and previous TB treatment was marginally significant (p = 0.10).
The cut-off for TOP OD values was determined to be 0.0854 using the laboratory criterion (e.g. +/-three standard deviations criterion). When we used ROC analysis with 100 random observations, we found the cut-off to be 0.088 leading to reclassification of only 4 individuals (Table E in S1 File). The area under the ROC curve was 0.86 for culture and 0.95 for the CRS using TOP OD as the diagnostic test (Fig G in S1 File) .
M. tuberculosis sequencing results
The relative frequency and distribution of 2-ponA genotypes differed significantly according to TOP OD values ( Fig 3 and Table 2 ; P = 0Á005); in particular, genotype 4 strains were mostly restricted to culture-negative samples with low ODs (Fig 3) . As shown in Fig 4, 2 -ponA genotypes had variable growth in culture (P = 0Á002).
Discussion
Our study provides strong evidence that the TOP TB assay accurately detects trace amounts of MTB DNA in the sputum of HIV-infected TB suspects who otherwise may yield a negative culture. Currently a culture diagnosis is the optimal reference standard for diagnosis. In the absence of culture to determine specificity, we established the validity of positive diagnosis using a composite reference standard and, most importantly, we sequenced MTB from culturenegative specimens. We used a reproducible genotyping method that is supported by the Purulent sputum category includes purulent and muco-purulent; Mucoid category includes mucoid and muco-salivary + Fisher's exact test.
genetic signature of a global collection of MTB clinical isolates representing all major phylogenetic lineages.
The natural history of pulmonary TB in HIV-uninfected adults is traditionally viewed as a sub-acute or chronic illness whose progression is accompanied by increasing bacterial loads in sputum, paralleling worsening disease severity on chest radiography. [4, 6] The paradigm states that patients with early TB are often smear-and culture-negative, and with an increase in severity, most patients become smear-negative/culture-positive first, and eventually, smearand culture-positive. However, a variety of epidemiologic studies including household contact investigations, molecular epidemiology and TB screening studies have demonstrated that the rate of disease progression in humans can be highly variable, perhaps as a consequence of low or stagnant MTB bacterial loads in sputum. [4, 35, 36] Furthermore, effective diagnostic and treatment programs that seek out cases to identify patients with most advanced disease (i.e. AFB smear-and culture-positive) may produce an epidemiological shift that results in the remaining populations with suspected TB of having a higher prevalence of early TB disease (i.e. smear-negative/culture-negative), that are the most difficult to confirm bacteriologically. [4] For example, in the U.S. during the 1980s, 90% of TB cases were confirmed by culture but this proportion decreased to 77% by 2013; [37] in some settings (e.g. Boston, MA and Alberta, Canada),~50% of notified TB cases are culture-negative. [38, 39] Therefore, culture-negative TB disease is a global problem resulting from both biological and epidemiological factors, for which there are currently limited solutions beyond the initiation of empirical antituberculous treatment based on clinical algorithms. [40] TOP TB enables enhanced detection of MTB in the sputum of TB suspects with HIV/AIDS, perhaps one of the largest and most vulnerable (together with children) populations with paucibacillary TB disease. In the early phase of assay development, our in vitro results suggested an analytical sensitivity of 1-4 colony-forming units (CFU) of MTB per mL, a level of detection greater than culture (e.g. 10-100 CFU/ml). With nullification of culture as the reference method, we anticipated challenges in validating the accuracy of our results. Several analytical methods have been recommended when dealing with imperfect reference methods such as mycobacterial cultures. [15, 32, 33, 41] The use of one of these-"discrepant analysis", or the use of a third test, is limiting because usually it is not applied consistently across all the specimens that are being examined, only the ones where the new test result conflicts with the "gold standard". [32, 33, 41] Our methods minimize the limitations of using discrepant analysis to evaluate NAATs because we tested all specimens, and because of the complete lack of overlap (lack of 'dependence') between the 3-ponA (diagnostic) and 2-ponA (genotyping) primers. Furthermore, the use of both clinical and epidemiologic data to act further as a referee, the latter demonstrating variability of genotypes according to TOP ODs add strength to the interpretation of a positive TOP in the face of a negative culture. Our results may be novel in the TB diagnostic field but the development of molecular tests with sensitivity superior to culture is not new in clinical settings. [42] Based on our results, the inclusion of 2-ponA genotypes into a composite reference standard to evaluate the performance of TOP follows standard practices in the TB diagnostic field [5, 15, 34] , and beyond. [43] Importantly, because the sensitivity of the primer used for sequencing is~8-10% lower that the diagnostic primer, 11/139 (8%) culture-negative/ TOP-positive specimens were adjudicated as false-positive TOP results, lowering the specificity of the assay in this study. In other ongoing studies with non-HIV sputum samples, the specificity of TOP has been 93% to 100% (data not shown).
Our results suggest that the TOP assay is sufficiently sensitive to overcome well-recognized difficulties with sputum procurement, such as inadequate specimen volumes and/or poor quality of specimens (e.g. excess saliva)-a problem that is thought to diminish diagnosis of TB in women disproportionately. [44] [45] [46] [47] This also raises the possibility of using sputum to diagnose paucibacillary TB when non-pulmonary clinical specimens (blood, gastric aspirates, urine, stool) have otherwise been thought necessary to establish the diagnosis. [5, 12, 48] Interestingly, our sequencing data establish a potential link between diagnosis, epidemiology and pathogenic behavior of MTB in humans. In particular, a high frequency of genotype 4 MTB isolates was noted in HIV-infected patients with low TOP ODs in Uganda. We had rarely observed this variant in the global collection of clinical isolates before these studies were started, raising the possibility that genotype 4 strains are uniquely adapted to HIV-infected hosts and cause predominantly culture-negative TB disease.
Our study has limitations. Our results were obtained by testing a convenience sample of low-volume, discarded, stored sputum specimens from an existing diagnostic clinical study; therefore, performance of the TOP assay may have been underestimated. The selection of the study population was solely based on when the TOP TB assay was ready for clinical testing (October 2013) rather than selection bias, as shown by the results of the parent study that included the entire population of HIV-infected patients. [24] The lack of clinical follow-up of subjects limits the clinical interpretation of certain results. For example, TOP was positive in numerous patients with a current or past history of treatment for TB, which complicated the clinical interpretation of negative cultures; interestingly, a similar phenomenon has recently been described with Xpert MTB/RIF, although a discrepant analysis was not performed. [49, 50] A positive TOP result likely represented either residual (dead) MTB DNA, viable but nonculturable organisms or bacterial persistence after treatment, the latter a potential harbinger of TB recurrence and/or risk of drug resistance. [17, 51, 52] Admittedly, detection of trace amounts of MTB DNA may be due to bacterial "spillage" from a dormant lung foci or low level Diagnosis of Culture-Negative Pulmonary Tuberculosis bacterial replication that may not require treatment. The colorimetric readout uses a study-specific cut-off value to establish the "Limit of Blank", a key assay parameter. [31] Finally, in its current embodiment, the TOP TB assay does not include provisions for detecting drug-resistant TB. However, the primary global need is for a rapid and reliable triage test. [5, 12] Conclusions Culture-negative TB is widespread, resulting from several biologic and epidemiologic factors. By shifting diagnostic emphasis to early detection, the TOP TB assay broadens sensitive and accurate detection of MTB across the entire clinical spectrum of TB disease. Our findings will require validation with clinical outcomes obtained prospectively. If the operating characteristics of the TOP assay are confirmed in future studies, it would be justified as a triage or "TB rule out" test.
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